P1658RENAL RECOVERY AFTER LIVER TRANASPLANTATION ALONE IN PATIENTS WITH LIVER CIRRHOSIS AND SEVERE CHRONIC KIDNEY DISEASE WITH NORMAL KIDNEY SIZE

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
EUN HYE YANG ◽  
Soon Bae Kim ◽  
Sung-Gyu Lee

Abstract Background and Aims Most guidelines recommend simultaneous liver-kidney transplantation (SLKT) in patients with liver cirrhosis (LC) and severe chronic kidney disease (CKD) over liver transplantation alone (LTA). CKD, however, is not irreversible. This study evaluates the reversibility of kidney disease after LTA based on kidney size. Method In this single-center retrospective study, we classified 90 patients with LC and severe CKD into 3 groups: normal kidney-LTA (NK-LTA, n=39), small kidney [both <9cm]-LTA (SK-LTA, n=40), and small kidney-SLKT (SK-SLKT, n=11). Baseline characteristics and renal recovery and survival outcomes were compared among 3 groups. Results The NK-LTA group had a lower percentage of hepatocellular carcinoma, a higher pre-LT eGFR, and a shorter duration of eGFR at <60 ml/min and pre-LT dialysis. This group, however, was older, received livers from a higher percentage of deceased donors and had a higher Child-Pugh score. Renal recovery, defined as no hemodialysis (HD) after LT, was found in 79% of those in the NK-LTA group, which was higher than 7.5% of those in the SK-LTA group. Renal survival, defined as patient survival without progression to HD or kidney transplant was found in 56% of patients in the NK-LTA group, which was higher than 2.5% of those of the SK-LTA group. Conclusion Patients with LC and severe CKD with normal kidney size may experience reversible kidney disease after LTA. Therefore, kidney after liver transplantation is recommended over SLKT for these patients.

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1066-P ◽  
Author(s):  
KATHERINE R. TUTTLE ◽  
MARK LAKSHMANAN ◽  
BRIAN L. RAYNER ◽  
ROBERT S. BUSCH ◽  
ALAN G. ZIMMERMANN ◽  
...  

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA


2006 ◽  
Vol 21 (5) ◽  
pp. 1257-1262 ◽  
Author(s):  
Csaba P. Kovesdy ◽  
Bhairvi K. Trivedi ◽  
Kamyar Kalantar-Zadeh ◽  
John E. Anderson

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i447-i447
Author(s):  
Liliana Tuta ◽  
Alina Stanigut ◽  
Bogdan Campineanu ◽  
Camelia Pana

Sign in / Sign up

Export Citation Format

Share Document